Mega Genomics (06667) released its 2025 interim results, reporting revenue of RMB81.3 million for the first half of the year, a 24.2% decrease compared to the same period in 2024. Net profit reached RMB27.3 million, falling 26.3% year-on-year. The decrease was mainly attributed to an adjustment in sales strategy and temporarily lower revenue, although cost optimization led to an increase in overall gross profit margin from 64.9% to 74.0%.

Consumer genetic testing services contributed RMB75.9 million in revenue, while cancer screening services generated RMB5.3 million. The company highlighted its broad product portfolio of 114 commercialized testing solutions and noted progress on multiple in vitro diagnostics pipeline products, including Alzheimer’s disease screening kits, colorectal and gastric cancer screening kits, and ApoE gene testing kits. Research and development remained a priority, with continued collaborations with medical institutions to advance IVD product registration and reinforce the company’s product matrix.

During the period, the company repurchased a total of 3,834,000 shares for approximately HK$32.9 million. Looking ahead, Mega Genomics (06667) outlined plans to further expand its consumer genetic testing and cancer screening offerings in China, strengthen research and development efforts, and optimize its service network while maintaining prudent investment and acquisition initiatives.